FGF21 and obesity due to melanocortin 4 receptor deficiency: Moreover, both recombinant FGF21 and FGF21 analogs have emerged as promising therapeutic drug candidates for metabolic disorders, including hepatic steatosis, obesity, insulin resistance and dyslipidemia, in several animal studies [34,35].